Prazepam Stats & Data

Depressant Benzodiazepine

Reapam Centrac Centrax Pozapam Prazene demetrin lysanxia prasepine

Chemical Class Benzodiazepine

Psychoactive Class Depressant

Half-Life Parent drug ~10–20 h; active metabolite (nordazepam) ~36–200 h; overall clinical elimination can span several days after repeated dosing.

Pharmacology

DrugBank

Half-life 36-200 hours State Solid Metabolism Hepatic.

Description

Prazepam is a benzodiazepine that is used in the treatment of anxiety disorders. It is a schedule IV drug in the U.S.

Mechanism of Action

Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.

Pharmacodynamics

Prazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Benzodiazepines may be habit-forming (causing mental or physical dependence), especially when taken for a long time or in high doses.

Toxicity

Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.

Indication

For the treatment of anxiety disorders.

Receptor Profile

Receptor Actions

Modulators

GABA-A receptor positive allosteric modulator (benzodiazepine site)

Receptor Binding

Translocator protein modulator

Effect Profile

Curated

Benzodiazepine 7.1

Strong anxiolysis and cognitive impairment with moderate sedation and euphoria

Anxiolysis×3

Sedation / Relaxation×2

Motor / Cognitive Impairment×1

Euphoria / Mood Lift×1

Based on reports from:

Erowid Experience Reports PsychonautWiki Prazepam

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

Parent drug ~10–20 h; active metabolite (nordazepam) ~36–200 h; overall clinical elimination can span several days after repeated dosing.

Addiction Potential

Moderate to high, as with other benzodiazepines; risk rises sharply with daily use >2–4 weeks, higher doses, polydrug depressant use, or substance-use history.

Tolerance Decay

Full tolerance 14d Half tolerance 7d Baseline ~28d

Sedative/anxiolytic tolerance tends to develop over weeks of daily use and decays slowly due to long‑acting metabolites. Figures are heuristic for planning conservative washouts, not clinical absolutes. Withdrawal risk persists even after perceived effects fade; always taper.

Cross-Tolerances

Other benzodiazepines

80% ●○○

Z‑drugs (zolpidem, zopiclone)

40% ●○○

Harm Reduction

drugs.wiki

• Prazepam is a long‑acting benzodiazepine prodrug whose primary active metabolite, desmethyldiazepam (nordazepam), has an extremely long and variable half‑life; with repeated dosing, effects and impairment can accumulate across days. Plan doses conservatively and avoid redosing within the same day unless fully assessed for residual sedation. Sources: DrugBank half‑life and CYP3A4 substrate listing; TripSit/Bluelight tables.

• Mixing benzodiazepines with other CNS depressants (alcohol, opioids, GHB/GBL, barbiturates, Z‑drugs) markedly increases the risk of fatal respiratory depression, blackout, and accidental injury; this combination drives a large share of drug‑related deaths. If any depressant has been used, skip further benzodiazepines and never ‘stack’ them to sleep. Sources: TripSit benzodiazepine harm‑reduction page; Erowid benzo caution.

• Grapefruit and other strong CYP3A4 inhibitors can raise prazepam/nordazepam exposure; DrugBank explicitly lists ‘avoid grapefruit’ and categorizes prazepam as a CYP3A4 substrate. Avoid grapefruit juice/products during use and for at least 48–72 h around dosing. Source: DrugBank food interactions/CYP3A4 substrate category.

• Contraindications and cautions include severe hepatic insufficiency (risk of encephalopathy), severe respiratory insufficiency, and sleep apnoea; start at reduced doses and titrate slowly in older or debilitated adults. Source: product‑style monograph reproduced on Drugs‑Forum.

• Therapeutic courses should be as short as possible (commonly ≤8–12 weeks including taper). Physical dependence can develop within weeks; abrupt cessation may precipitate severe withdrawal (anxiety rebound, agitation, seizures) and should be avoided. Taper gradually under supervision. Sources: Drugs‑Forum monograph; TripSit warnings that benzo withdrawal can be fatal.

• Driving and hazardous tasks: next‑day cognitive/motor impairment is common with long‑acting benzodiazepines. Do not drive or operate machinery during acute effects, after dose increases, or the morning after evening dosing—especially with polydrug use or sleep debt. Source: TripSit HR page (explicit ‘inability to drive’).

• Dose equivalence varies between tables; a commonly cited range is prazepam 10–20 mg ≈ diazepam 10 mg, with one clinical compilation listing 15 mg ≈ 10 mg diazepam. Use equivalence only as rough guidance when switching, then cross‑titrate carefully. Sources: TripSit benzo table; Bluelight equivalency post.

• Caffeine can subjectively mask sedation without restoring psychomotor performance; DrugBank lists ‘limit caffeine’. Avoid using stimulants to ‘offset’ benzo sedation; this increases risk‑taking while still impaired. Source: DrugBank food interactions; general benzo HR consensus.

• Paradoxical agitation, disinhibition, and anterograde amnesia can occur, especially at higher doses, in children/older adults, or with alcohol. If paradoxical reactions emerge, discontinue and seek medical guidance. Sources: Drugs‑Forum monograph; Erowid benzo pages.